FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W577449728> ?p ?o ?g. }

• W577449728 endingPage "206" @default.
• W577449728 startingPage "206" @default.
• W577449728 abstract "Abstract Introduction Acquired hemophilia A (AHA) is a rare bleeding disorder, resulting from auto-antibodies to human factor VIII (hFVIII). The challenges created by the management of AHA and the co-morbidities present in this typically elderly population, can be managed by a recombinant, highly pure, B-domain deleted, porcine sequence FVIII (OBI-1) that is not generally susceptible to the inhibitory activity of anti-human FVIII antibodies. Treatment with OBI-1 allows for monitoring of FVIII levels which provides a reproducible and objective surrogate predictor of hemostasis. Eradication of hFVIII inhibitors with immunosuppressive therapy is critical for disease management. During immunosuppression, the patient transitions from a bleeding state at initial presentation to a relative hypercoagulable state which can be an issue in patients who are susceptible to thromboembolic events due to their comorbidities. This transition period is of most concern especially when using traditionally utilized bypassing agents that cannot be monitored. OBI-1 enables measurement of FVIII levels, guiding dosing and enhancing treatment safety during this critical period. Methods This global, prospective, multi-center phase 2/3 open label clinical trial investigates the efficacy and safety of OBI-1 in the treatment of serious bleeds in adults with AHA conducted under ICH guidelines and local IRB/Ethics Committee oversight. Primary efficacy endpoint was assessed at 24 hours (eg. effective, partially effective). All subjects (N= 18) presented with a serious bleed and were treated with an initial dose of OBI-1 (200 U/kg), followed by additional doses based on the subject's target factor VIII levels, anti-OBI-1 titer, and clinical factors. Results In all 18 subjects, a positive response (14 effective/4 partially effective) to treatment was observed at 24 hours. This positive response to OBI-1 treatment was seen by 8 hours in 14/18 of the subjects and at 16 hours in 16/18 of the subjects. Median total exposure to OBI-1 per subject was 1782.5 U/kg. The median total first dose was 14,000 U. For subjects who received additional doses of OBI-1, the median dose was reduced from the initial dose, but did not differ considerably over subsequent doses (9180 to 13561 U; median 11000 U). The majority of subjects (17/18) received concomitant immunosuppressive therapies. No related serious adverse reactions occurred. Non-serious adverse events related to treatment were noted in 5/18 (27.8%) subjects. One subject had mild tachycardia, hypotension and constipation. One subject had 2 instances of mild PICC line occlusion. One subject had a mild hypofibrogenemia. All of these adverse effects completely resolved. Three subjects developed anti-porcine inhibitors after infusion of study drug (range 8-108 BU) and two were discontinued from treatment. Anti-porcine inhibitors were detected prior to infusion in 6/18 patients (range 0.8-29 BU). All of these subjects had a favorable clinical response at 24 hours post-OB-1 infusions. Conclusions Data from this prospective study demonstrate OBI-1 as a safe and effective treatment of bleeding episodes in patients with AHA, with the added advantage over other bypass therapies of allowing FVIII monitoring throughout treatment and healing phase. Disclosures: Kruse-Jarres: Baxter Healthcare: Consultancy; Bayer HealthCare: Consultancy; Biogen IDEC: Consultancy; Grifols: Consultancy; Kedrion: Consultancy; Novo Nordisk: Consultancy. St. Louis:CSL Behring: Research Funding; Octapharma: Consultancy, Research Funding; Baxter: Consultancy; Novo Nordisk: Honoraria. Shapiro:Kedrion Biopharma: Consultancy; Chugai Pharma USA: Consultancy; Biogen IDEC: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Bayer HealthCare: Membership on an entity’s Board of Directors or advisory committees; Novo Nordisk: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Baxter Healthcare: Consultancy, Membership on an entity’s Board of Directors or advisory committees. Chowdary:Baxter Healthcare: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Travel grant Other; Novo Nordisk: Honoraria, Research Funding, Travel grant, Travel grant Other; Bayer HealthCare: Honoraria, Travel grant, Travel grant Other; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Travel grant, Travel grant Other; CSL Behring: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Travel grant Other; Biogen IDEC: Honoraria, Travel, Travel Other. Drebes:Octapharma: Travel grant Other; CSL Behring: Travel grant, Travel grant Other; Leo-pharma: Travel grant, Travel grant Other; Bayer Healthcare: Consultancy, Honoraria. Gomperts:Baxter Healthcare: Consultancy; Asklepios Biopharmaceutoicals Inc: Consultancy; Cangene Inc: Consultancy. Chapman:Baxter Healthcare: Employment. Mo:Baxter Healthcare: Employment. Novack:Baxter Healthcare: Employment. Farin:Baxter Healthcare: Employment." @default.
• W577449728 created "2016-06-24" @default.
• W577449728 creator A5002437950 @default.
• W577449728 creator A5002765547 @default.
• W577449728 creator A5012761162 @default.
• W577449728 creator A5038597185 @default.
• W577449728 creator A5047176224 @default.
• W577449728 creator A5062825203 @default.
• W577449728 creator A5064355731 @default.
• W577449728 creator A5067583447 @default.
• W577449728 creator A5069623401 @default.
• W577449728 creator A5070415689 @default.
• W577449728 creator A5086130517 @default.
• W577449728 creator A5086373140 @default.
• W577449728 date "2013-11-15" @default.
• W577449728 modified "2023-10-16" @default.
• W577449728 title "Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial" @default.
• W577449728 doi "https://doi.org/10.1182/blood.v122.21.206.206" @default.
• W577449728 hasPublicationYear "2013" @default.
• W577449728 type Work @default.
• W577449728 sameAs 577449728 @default.
• W577449728 citedByCount "0" @default.
• W577449728 crossrefType "journal-article" @default.
• W577449728 hasAuthorship W577449728A5002437950 @default.
• W577449728 hasAuthorship W577449728A5002765547 @default.
• W577449728 hasAuthorship W577449728A5012761162 @default.
• W577449728 hasAuthorship W577449728A5038597185 @default.
• W577449728 hasAuthorship W577449728A5047176224 @default.
• W577449728 hasAuthorship W577449728A5062825203 @default.
• W577449728 hasAuthorship W577449728A5064355731 @default.
• W577449728 hasAuthorship W577449728A5067583447 @default.
• W577449728 hasAuthorship W577449728A5069623401 @default.
• W577449728 hasAuthorship W577449728A5070415689 @default.
• W577449728 hasAuthorship W577449728A5086130517 @default.
• W577449728 hasAuthorship W577449728A5086373140 @default.
• W577449728 hasConcept C126322002 @default.
• W577449728 hasConcept C159654299 @default.
• W577449728 hasConcept C187212893 @default.
• W577449728 hasConcept C203014093 @default.
• W577449728 hasConcept C203092338 @default.
• W577449728 hasConcept C2777288759 @default.
• W577449728 hasConcept C2778589496 @default.
• W577449728 hasConcept C2778961111 @default.
• W577449728 hasConcept C2780252810 @default.
• W577449728 hasConcept C2908647359 @default.
• W577449728 hasConcept C535046627 @default.
• W577449728 hasConcept C71924100 @default.
• W577449728 hasConcept C99454951 @default.
• W577449728 hasConceptScore W577449728C126322002 @default.
• W577449728 hasConceptScore W577449728C159654299 @default.
• W577449728 hasConceptScore W577449728C187212893 @default.
• W577449728 hasConceptScore W577449728C203014093 @default.
• W577449728 hasConceptScore W577449728C203092338 @default.
• W577449728 hasConceptScore W577449728C2777288759 @default.
• W577449728 hasConceptScore W577449728C2778589496 @default.
• W577449728 hasConceptScore W577449728C2778961111 @default.
• W577449728 hasConceptScore W577449728C2780252810 @default.
• W577449728 hasConceptScore W577449728C2908647359 @default.
• W577449728 hasConceptScore W577449728C535046627 @default.
• W577449728 hasConceptScore W577449728C71924100 @default.
• W577449728 hasConceptScore W577449728C99454951 @default.
• W577449728 hasIssue "21" @default.
• W577449728 hasLocation W5774497281 @default.
• W577449728 hasOpenAccess W577449728 @default.
• W577449728 hasPrimaryLocation W5774497281 @default.
• W577449728 hasRelatedWork W2046564088 @default.
• W577449728 hasRelatedWork W2051507950 @default.
• W577449728 hasRelatedWork W2054434160 @default.
• W577449728 hasRelatedWork W2089799535 @default.
• W577449728 hasRelatedWork W2090074106 @default.
• W577449728 hasRelatedWork W2119339335 @default.
• W577449728 hasRelatedWork W2375557308 @default.
• W577449728 hasRelatedWork W2387503964 @default.
• W577449728 hasRelatedWork W2947337648 @default.
• W577449728 hasRelatedWork W4214669266 @default.
• W577449728 hasVolume "122" @default.
• W577449728 isParatext "false" @default.
• W577449728 isRetracted "false" @default.
• W577449728 magId "577449728" @default.
• W577449728 workType "article" @default.